Browsing by Author "Ayles HM"

Filter results by typing the first few letters
Now showing 1 - 2 of 2
  • Thumbnail Image
    Item
    Final Analysis of a Trial of M72/AS01
    (2019-Dec-19) Tait DR; Hatherill M; Van Der Meeren O; Ginsberg AM; Van Brakel E; Salaun B; Scriba TJ; Akite EJ; Ayles HM; Bollaerts A; Demoitié MA; Diacon A; Evans TG; Gillard P; Hellström E; Innes JC; Lempicki M; Malahleha M; Martinson N; Mesia Vela D; Muyoyeta M; Nduba V; Pascal TG; Tameris M; Thienemann F; Wilkinson RJ; Roman F
    BACKGROUND: Results of an earlier analysis of a trial of the M72/AS01 METHODS: From August 2014 through November 2015, we enrolled adults 18 to 50 years of age with RESULTS: A total of 3575 participants underwent randomization, of whom 3573 received at least one dose of M72/AS01 CONCLUSIONS: Among adults infected with
  • Thumbnail Image
    Item
    Phase 2b Controlled Trial of M72/AS01
    (2018-Oct-25) Van Der Meeren O; Hatherill M; Nduba V; Wilkinson RJ; Muyoyeta M; Van Brakel E; Ayles HM; Henostroza G; Thienemann F; Scriba TJ; Diacon A; Blatner GL; Demoitié MA; Tameris M; Malahleha M; Innes JC; Hellström E; Martinson N; Singh T; Akite EJ; Khatoon Azam A; Bollaerts A; Ginsberg AM; Evans TG; Gillard P; Tait DR
    BACKGROUND: A vaccine to interrupt the transmission of tuberculosis is needed. METHODS: We conducted a randomized, double-blind, placebo-controlled, phase 2b trial of the M72/AS01 RESULTS: We report the primary analysis (conducted after a mean of 2.3 years of follow-up) of the ongoing trial. A total of 1786 participants received M72/AS01 CONCLUSIONS: M72/AS01